

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 2 of 9	Attorney Docket Number	MSK.P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		AGHAJANIAN ET AL, Phase II Study of Dose-Dense High-Dose Chemotherapy Treatment with Peripheral-Blood Progenitor-Cell Support as Primary Treatment for Patients with Advanced Ovarian Cancer, Journal of Clinical Oncology, 1998, Page(s) 1852-1860, Volume 16, Number 5	
ESO		BHARDWAJ ET AL, An Intensive Sequenced Adjuvant Chemotherapy Regimen for Breast Cancer, Cancer Investigation, 1993, Page(s) 6-9, Volume 11	
ESO		BUDMAN ET AL, Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer, Journal of the National Cancer Institute, 1998, Page(s) 1205-1211, Volume 90, Number 16	
ESO		CITRON ET AL, Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 8741, Journal of Clinical Oncology, 2003; Page(s) 1431-1439; Volume 21; Number 8	
ESO		COSTANZA ET AL, Safety and Efficacy of Using a Single Agent or a Phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized Study-Cancer and Leukemia Group B 8642, Journal of Clinical Oncology, 1999, Page(s) 1397-1406, Volume 17, Number 5	
ESO		CROWN ET AL, Rapid Delivery of Multiple High-Dose Chemotherapy Courses with Granulocyte Colony-Stimulating Factor and Peripheral Blood-Derived Hematopoietic Progenitor Cells, Journal of National Cancer Institute, 12/16/1992, Page(s) 195-1936, Volume 84, Number 24	
ESO		CROWN ET AL, Rapid Administration of Multiple Cycles of High-Dose Myelosuppressive Chemotherapy in Patients with Metastatic Breast Cancer, Journal of Clinical Oncology, 1993, Page(s) 1144-1149, Volume 11, Number 6	
ESO		CROWN ET AL, High-Intensity Chemotherapy with Hematopoietic Support in Breast Cancer, Pisa Symposia in Oncology: From Biology to Therapy, 1993, Page(s) 378-388, Volume 698	
ESO		CROWN ET AL, High-dose Chemotherapy of Breast Cancer: Current Status and Developmental Strategies, European Journal of Cancer, 1995, Page(s) 809-811, Volume 31A, Number 5	
ESO		CROWN ET AL, Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer, 1995; Page(s) 21-26; Number 6	
ESO		CROWN ET AL, High-dose chemotherapy of breast cancer, Supplement of The Canadian Journal of Oncology, 1995, Page(s) 80-82, Volume 5, Number 1	

Examiner Signature	<i>Eric S. Olson</i>	Date Considered	4/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 3 of 9	Attorney Docket Number	MSK.P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		FENNELLY, Simultaneous Dose Escalation and Schedule Intensification of Carboplatin-based Chemotherapy Using Peripheral Blood Progenitor Cells and Filgrastim: A Phase I Trial, Cancer Research, 12/1/1994, Page(s) 6137-6142, Volume 54	
ESO		FENNELLY ET AL, Clinical Potential of Hemopoietic Growth-Factor Support for High-Dose Chemotherapy, 1996, Page(s) 299-311, Publisher: Cambridge University Press	
ESO		FENNELLY ET AL, Phase I and Pharmacologic Study of Paclitaxel Administered Weekly in Patients with Relapsed Ovarian Cancer, Journal of Clinical Oncology, 1997, Page(s) 187-192, Volume 15, Number 1	
ESO		FENNELLY ET AL, High-intensity Chemotherapy with Peripheral Blood Progenitor Cell Support, Seminars in Oncology, 4/1994, Page(s) 21-25, Volume 21, Number 2	
ESO		FENNELLY ET AL, Dose Escalation of Paclitaxel with High-Dose Cyclophosphamide, with Analysis of Progenitor-Cell Mobilization and Hematologic Support of Advanced Ovarian Cancer Patients Receiving Rapidly Sequenced High-Dose Carboplatin/Cyclophosphamide Courses, Journal of Clinical Oncology, 5/1995, Page(s) 1160-1166, Volume 13, Number 5	
ESO		FORNIER ET AL, Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide versus Concurrent Paclitaxel and Cyclophosphamide: 5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma, Clinical Cancer Research, 2001, Page(s) 3934-3941, Volume 7	
ESO		GILEWSKI ET AL, Cytokinetics of Neoplasia, The Molecular Basis of Cancer, 1995, Page(s) 143-159	
ESO		GILEWSKI ET AL, Cytokinetics and Breast Cancer Chemotherapy, Diseases of Breast Cancer, 1995, Page(s) 751-768	
ESO		GILEWSKI ET AL, Cytokinetics, Principles of Chemotherapy, 2000, Page(s) 511-538	
ESO		HENDERSON ET AL; In Reply to: Benefit of Paclitaxel in Estrogen Receptor-Negative Versus Estrogen Receptor-Positive Early Breast Cancer; Journal of Clinical Oncology; 2003; Page(s) 4465-4466	
ESO		HENDERSON ET AL, Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy Regimen for Patients with Node-Positive Primary Breast Cancer, Journal of Clinical Oncology, 3/15/2003, Page(s) 976-983, Volume 21, Number 6	

Examiner Signature	<i>Eric S. Olson</i>	Date Considered	4/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 4 of 9	Attorney Docket Number	MSK,P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		HUDIS ET AL, Dose-Intensive Sequential Crossover Adjuvant Chemotherapy for Women with High Risk Node-Positive Primary Breast Cancer, Adjuvant Therapy of Cancer, 1993, Page(s) 214-219	
ESO		HUDIS ET AL, Event-Free Survival After Sequential Dose-Dense Doxorubicin (A), Paclitaxel (T) and Cyclophosphamide (C) in women (pts) with > 4 Positive (+) Axillary Lymph Nodes (LN), Breast Cancer Research Treatment, 1996, Page(s) 232, Volume 41	
ESO		HUDIS ET AL, Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel, Cancer Investigation, 1998, Page(s) 67-71, Volume 16	
ESO		HUDIS ET AL, 5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women with High-Risk Node-Positive Breast Cancer: A Phase II Study, Journal of Clinical Oncology, 1999, Page(s) 1118-1126, Volume 17, Number 4	
ESO	A	HUDIS ET AL, Sequential Adjuvant Therapy with Doxorubicin/Paclitaxel/Cyclophosphamide for Resectable Breast Cancer Involving Four or More Axillary Nodes, Seminars in Oncology, 1995, Page(s) 18-23, Volume 22, Number 6	
ESO		HUDIS ET AL, Sequential Adjuvant Therapy: The Memorial Sloan-Kettering Cancer Center Experience, Seminars in Oncology, 1996, Page(s) 58-64, Volume 23, Number 1	
ESO		HUDIS ET AL, Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy, Journal of Clinical Oncology, 1999, Page(s) 93-100, Volume 17, Number 1	
ESO		HUDIS ET AL, Sequential Single-Agent Chemotherapy Versus Simultaneous Combination Chemotherapy for Primary and Metastatic Breast Cancer, Seminars in Breast Disease, 1999, Page(s) 180-192, Volume 2, Number 2	
ESO		LICHTMAN ET AL, Phase I Trial of Granulocyte-Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 weeks; a Cancer and Leukemia Group B Study, Journal of the National Cancer Institute, 8/18/1993, Page(s) 1319-1326, Volume 85, Number 16	
ESO		MCCAFFREY EL AL; A Phase II and Pharmacologic Study of Taxol (T) by Weekly One-Hour (a-h) Infusion in the Treatment of Patients (pts) with Metastatic Breast Cancer (MBC);1997; Page(s) 234; Number 41	
ESO		NORTON ET AL, Tumor Growth Kinetics, Therapeutic Differentials, and Design of Treatment Schedules, Cancer Treatment Reports, 5/1978, Page(s) 845-847, Volume 62, Number 5	

Examiner Signature	<i>E. E. Olson</i>	Date Considered	7/17/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 5 of 9	Attorney Docket Number	MSK.P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		NORTON, Thoughts on a Role for Cell Kinetics in Cancer Chemotherapy, Controversies in Cancer: Design of Trials and Treatment, 1979, Page(s) 105-115	
ESO		NORTON, Mathematical Interpretation of Tumor Growth Kinetics, Clinical Interpretation and Practice of Cancer Chemotherapy, 1982, Page(s) 53-70	
ESO		NORTON, A Gompertzian Model of Human Breast Cancer Growth, Cancer Research, 12/15/1988, Page(s) 7067-7071, Volume 48	
ESO		NORTON, Reply to the editor, Cancer Research, 8/9/1989, Page(s) 6444, Volume 49	
ESO		NORTON, Biology of Residual Breast Cancer after Therapy: A Kinetic Interpretation, Program of Clinical Biology Research, 1990, Page(s) 109-132	
ESO		NORTON ET AL., Potential Innovations in Scheduling of Cancer Chemotherapy, Important Advanced Oncology, 1991, Page(s) 57-72	
ESO		NORTON, Clinical Aspects of Cell and Tumor Growth Kinetics, 1991, Page(s) 409-414, Publisher: William & Wilkens	
ESO		NORTON, Tumor Growth Kinetics, Manual of Clinical Oncology, 1991, Page(s) 52-69, Publisher: Elsevier	
ESO		NORTON, Evolving concepts in the adjuvant systemic therapy of operable breast cancer, Cancer Treatment Research, 1992, Page(s) 3-25, Number 60, Publisher: Kluwer Academic Publishers	
ESO		NORTON; The Norton-Simon Hypothesis; 1992; Page(s) 36-53; Publisher: Williams & Wilkins	
ESO		NORTON ET AL, Cytokinetics, Adjuvant Therapy of Primary Breast Cancer IV, 1993, Page(s) 598-617	

Examiner Signature	<i>Eric S. Olson</i>	Date Considered	4/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 6 of 9	Attorney Docket Number	MSK.P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		NORTON, Kinetic Concepts in the Treatment of Breast Cancer, Recent Results in Cancer Research, 1993, Page(s) 1-6, Volume 127	
ESO		NORTON, The Norton-Simon Hypothesis, The Chemotherapy Source Book, 1996, Page(s) 43-61	
ESO		NORTON, Conceptual Basis for Advances in the Systemic Drug Therapy of Breast Cancer, Seminars in Oncology, 1997, Page(s) S11-2 - S11-12, Volume 24, Number 4	
ESO		NORTON, Evolving Concepts in the Systemic Drug Therapy of Breast Cancer, Seminars in Oncology, 1997, Page(s) S10-3 - S10-10, Volume 24, Number 4	
ESO		NORTON, Integration of New Therapies into the Management of Breast Cancer, Oncology, 1998, Page(s) 1-4, Volume 12, Number 1	
ESO		NORTON, Kinetic Concepts in the Systemic Drug Therapy of Breast Cancer, Seminars in Oncology, 1999, Page(s) 11-20, Volume 26, Number 1	
ESO		NORTON, Adjuvant Breast Cancer Therapy: Current Status and Future Strategies-Growth Kinetics and the Improved Drug Therapy of Breast Cancer, Seminars in Oncology, 1999, Page(s) 1-4, Volume 26, Number 1	
ESO		NORTON, Chemotherapy Dose, Schedule, and the Modern Treatment of Primary Breast Cancer, Cancer Investigation, 2000, Page(s) 55-57	
ESO		NORTON, Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant Therapy, The Oncologist, 2001, Page(s) 30-35, Volume 6, Number 3	
ESO		NORTON, Salvage Chemotherapy of Breast Cancer; Seminars in Oncology; 1994, Page(s) 19-24, Volume 21, Number 4	
ESO		NORTON ET AL, Innovative approaches to the treatment of advanced breast cancer: introduction, Seminars in Oncology, 1997, Page(s) S101-S102, Volume 24, Number 4	

Examiner Signature		Date Considered	4/17/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 7 of 9	Attorney Docket Number	MSK.P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		NORTON, Introduction to Clinical Aspects of Preneoplasia: a Mathematical Relationship between Stromal Paracrine Autonomy and Population Size, 1993, Page(s) 269-275, Publisher: Ares-Serono Symposia Publications	
ESO		NORTON, Larry Norton-President-elect of ASCO, Lancet Oncology, 2000, Page(s) 189-192, Volume 1	
ESO		NORTON ET AL, Tumor Size, Sensitivity to Therapy, and Design of Treatment Schedules, Cancer Treatment Reports, 10/1977, Page(s) 1307-1317, Volume 61, Number 7	
ESO		NORTON, Implications of Kinetic Heterogeneity in Clinical Oncology, Seminars in Oncology, 9/1985, Page(s) 231-249, Volume 12, Number 3	
ESO		NORTON ET AL, Predicting the course of Gompertzian growth, Nature, 12/9/1976, Page(s) 542-545, Volume 264	
ESO		NORTON ET AL, Growth Curve of an Experimental Solid Tumor Following Radiotherapy, J National Cancer Institute, 1977, Page(s) 1735-1741, Volume 58, Number 6	
ESO		NORTON ET AL, New Thoughts on the Relationship of Tumor Growth Characteristics to Sensitivity to Treatment, Methods in Cancer Research, 1979, Page(s) 53-91, Volume XVII	
ESO		NORTON, Cell Kinetics in Normal Tissues and in Tumors of the Young, Cancer in the Young, 1982, Page(s) 53-82	
ESO		NORTON, Tumor Growth Kinetics, The Mount Sinai Journal of Medicine, 3/1985, Page(s) 161-164, Volume 52, Number 3	
ESO		NORTON ET AL, The Norton-Simon Hypothesis Revisited, 1/1986, Page(s) 163-168, Volume 70, Number 1	
ESO		PERLOFF ET AL, Postsurgical Adjuvant Chemotherapy of Stage II Breast Carcinoma with or without Crossover to a Non-Cross-Resistant Regimen: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, 1996, Page(s) 1589-1598, Volume 14, Number 5	

Examiner Signature	<i>Eric S. Olson</i>	Date Considered	4/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 8 of 9	Attorney Docket Number	MSK.P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		RAPTIS ET AL, Rapid Hematologic Recovery Following CD34+ Selected Versus Unselected Peripheral Blood Progenitor Cell (PBPC) + Filgrastim (G) Rescue of Sequential High Dose Chemotherapy (HDC) in Patients (PTS) with Metastatic Breast Cancer (MBC), Blood, 1995, Page(s) 1601, Volume 86	
ESO		REICHMAN ET AL, Paclitaxel and Recombinant Human Granulocyte Colony-Stimulating Factor as Initial Chemotherapy for Metastatic Breast Cancer, Journal of Clinical Oncology, 1993, Page(s) 1943-1951, Volume 11, Number 10	
ESO		REICHMAN ET AL, Taxol and Recombinant Human Granulocyte Colony-Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer, Pisa Symposia in Oncology: From Biology to Therapy, 1993, Page(s) 398-401, Volume 698	
ESO		SCHER ET AL, Chemotherapy for Urothelial Tract Malignancies: Breaking the Deadlock, Seminars in Surgical Oncology, 1992, Page(s) 316-341, Volume 8	
ESO		SEIDMAN ET AL, Preliminary Experience with Paclitaxel (TAXOL) Plus Recombinant Human Granulocyte Colony-Stimulating Factor in the Treatment of Breast Cancer, Seminars in Oncology, 1993, Page(s) 40-45, Volume 20, Number 4	
ESO		SEIDMAN, Taxol plus recombinant human granulocyte colony stimulating factor as salvage chemotherapy for metastatic breast cancer, Cancer Treatment Update, 1994, Page(s) 172-175	
ESO		SEIDMAN ET AL, Taxol (Paclitaxel) plus Recombinant Human Granulocyte Colony-Stimulating Factor in the Treatment of Metastatic Breast Cancer, Oncology, 1994, Page(s) 33-39, Volume 51	
ESO		SEIDMAN ET AL, Phase II Trial of Weekly 1-Hour Taxol and Herceptin for Metastatic Breast Cancer: Toward Further Exploitation of Proven Synergistic Antitumor Activity, Cancer Investigation, 1999, Page(s) 44-45, Volume 17	
ESO		SEIDMAN, Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer with Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification, Journal of Clinical Oncology, 2001, Page(s) 2587-2595, Volume 19, Number 10	
ESO		SEIDMAN ET AL, Dose-Dense Therapy with Paclitaxel Via Weekly 1-Hour Infusion: Preliminary Experience in the Treatment of Metastatic Breast Cancer, 1997, Page(s) S17-72 - S17-76, Volume 24, Number 5	
ESO		SEIDMAN ET AL, Dose-Dense Therapy with Weekly 1-Hour Paclitaxel Infusions in the Treatment of Metastatic Breast Cancer, Journal of Clinical Oncology, 1998, Page(s) 3353-3361, Volume 16, Number 10	

Examiner Signature	<i>Eric S. Olson</i>	Date Considered	4/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 9 of 9	Attorney Docket Number	MSK,P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		SURBONE ET AL, Kinetic Concepts in the Treatment of Breast Cancer, Pisa Symposia in Oncology: From Biology to Therapy, 1993, Page(s) 48-62, Volume 698	
ESO		SURBONE ET AL, Le basi cinetiche delle neoplasie mammarie, Minerva Medica, 1994, Page(s) 7-16, Volume 85, Number 1-2	
ESO		SURBONE ET AL, Cytokinetics, Cancer Medicine 4th edition, 1996, Page(s) 769-798	
ESO		VAHDAT ET AL, Rapidly Cycled Courses of High-Dose Alkylating Agents Supported by Filgrastim and Peripheral Blood Progenitor Cells in Patients with Metastatic Breast Cancer, Clinical Cancer Research, , Page(s) 1267-1273, Volume 1	
ESO	B	WINER ET AL, A Randomized Trial of Three Doses of Paclitaxel in Patients with Metastatic Breast Cancer, Seminar in Oncology, 1999, Page(s) 9, Volume 26	
ESO	C	WOOD ET AL, Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma, The New England Journal of Medicine, 5/5/1994, Page(s) 1253-1259, Volume 330, Number 18	
ESO		YORKE ET AL, Modeling the Development of Metastases from Primary and Locally Recurrent Tumors: Comparison with a Clinical Data Base for Prostatic Cancer, Cancer Research, 7/1/2993, Page(s) 2987-2993, Volume 53	

Examiner Signature	<i>Eric R. Olson</i>	Date Considered	4/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.